{"id":"bd-mdi-80-g","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Nervousness"}]},"_chembl":{"chemblId":"CHEMBL1588467","moleculeType":"Small molecule","molecularWeight":"332.31"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Budesonide is an inhaled corticosteroid that suppresses airway inflammation by binding glucocorticoid receptors, while formoterol is a long-acting beta-2 agonist that relaxes bronchial smooth muscle and improves airflow. Together, they provide both anti-inflammatory and bronchodilatory effects in a metered-dose inhaler formulation.","oneSentence":"BD MDI 80 µg is a budesonide/formoterol combination inhaler that reduces airway inflammation and improves bronchodilation for respiratory disease management.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:22:28.081Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT03847896","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma","status":"COMPLETED","sponsor":"Bond Avillion 2 Development LP","startDate":"2019-03-20","conditions":"Asthma","enrollment":1001},{"nctId":"NCT03772223","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics of Budesonide and Albuterol Delivered by PT027 Compared With PT007 and PT008 Administered Separately.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-01-21","conditions":"Healthy Volunteers","enrollment":91},{"nctId":"NCT02105012","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2014-04-01","conditions":"Asthma","enrollment":147}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PT008"],"phase":"phase_2","status":"active","brandName":"BD MDI 80 µg","genericName":"BD MDI 80 µg","companyName":"Pearl Therapeutics, Inc.","companyId":"pearl-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BD MDI 80 µg is a small molecule medication used to treat asthma. It is administered via a metered dose inhaler, which delivers a combination of budesonide and albuterol sulfate.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}